Events

Applications for Lundbeck's first Golden Ticket are now open! 

This Golden Ticket call is a special opportunity supported by LabCentral's Innovation Partner, Lundbeck A/S. 

Apply today here! Applications will close on August 18, 2025, at 11:59 p.m.

Lundbeck is calling for applications developing new therapeutic solutions within the following key areas of neuro-rare diseases affecting the central and peripheral nervous system*:

• Causal biology defined segments of neurodegenerative diseases.
• Monogenetic disorders with unmeet brain symptom need.
• Repeat expansion diseases e.g., Huntington’s disease, Friedreich’s ataxia, spinocerebellar ataxias, etc.
• Neuromuscular diseases e.g., Amyotrophic lateral sclerosis, Duchenne muscular dystrophy, etc.
• Neuro-inflammatory diseases e.g., demyelinating diseases like progressive multiple sclerosis, neuromyelitis optica spectrum disorder, etc
• Epilepsies with causal biology insight e.g., epilepsy syndromes, developmental and epileptic encephalopathy and other biologically defined segments

Modalities: small molecules, oligonucleotides, and large molecules such as antibodies or peptides**

Applications incorporating new technology platforms enabling RNA targeting to the nervous system, digital/AI tools, novel humanized model systems or biomarkers to enable drug discovery or development for neuro-rare diseases and are applicable for brain health more broadly are also of particular interest.

* Some indications within brain health are known to display sex-specific differences, and this should be accounted for in the application. 

**Out-of-scope: cell and gene therapies, repurposing of already marketed assets, over-the-counter solutions, and supplements.